Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Vertex Pharmaceuticals' EVP, Amit Sachdev, reported a disposition of 2,057 common shares valued at $468.41 each, primarily for tax purposes.

Vertex Pharmaceuticals' EVP, Chief Commercial Officer, Duncan McKechnie, reported a sale of 1,127 common shares at $468.41 each under a pre-arranged 10b5-1 plan.

Vertex Pharmaceuticals CEO Reshma Kewalramani disposed of 8,297 common stock shares to cover tax withholding obligations at a price of $468.41 per share.

Vertex Pharmaceuticals' EVP and Chief Scientific Officer, Mark E. Bunnage, reported the sale of common stock, including shares withheld for tax obligations, under a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, disposed of 2,145 shares of common stock to cover tax liabilities at a price of $468.41 per share.

Vertex Pharmaceuticals' EVP and Chief Legal Officer, Jonathan Biller, reported the sale of company common stock totaling 3,555 shares.

Vertex Pharmaceuticals' EVP, Edward Atkinson, sold 2,623 shares of common stock in pre-planned transactions totaling over $1.2 million.

Vertex Pharmaceuticals' SVP & Chief Accounting Officer, Kristen Ambrose, sold 1,968 shares of common stock in pre-planned transactions.

Vertex Pharmaceuticals' EVP, Chief Operating Officer, and Chief Financial Officer, Charles F. Wagner Jr., acquired 13,600 shares of common stock through the vesting of performance stock unit awards.

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, acquired 11,749 shares of common stock through performance-based awards.

Vertex Pharmaceuticals executive Amit Sachdev was awarded 11,749 performance shares, reflecting the attainment of performance goals.

Vertex Pharmaceuticals' EVP, Chief Commercial Officer Duncan McKechnie, acquired 6,800 shares of common stock through the vesting of performance stock units.

Vertex Pharmaceuticals' Executive Chairman, Jeffrey M. Leiden, acquired 9,012 shares of common stock through the vesting of performance-based awards.

Vertex Pharmaceuticals CEO Reshma Kewalramani received 38,857 shares of common stock through performance-based awards.

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, earned 11,333 performance shares, reflecting the attainment of performance-vesting requirements.

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, acquired 9,068 shares of common stock through the vesting of performance stock unit awards.

Vertex Pharmaceuticals' EVP, Chief Technical Operations Officer, Edward Morrow Atkinson III, acquired 7,817 shares of common stock through performance-based awards.

Vertex Pharmaceuticals' SVP & Chief Accounting Officer, Kristen Ambrose, acquired 4,250 shares of common stock through the vesting of performance-based awards.

Vertex Pharmaceuticals' Chief Scientific Officer, David Altshuler, acquired 11,194 shares of common stock through the vesting of performance-based awards.

Vertex Pharmaceuticals director Suketu Upadhyay acquired 80.316 deferred stock units, increasing his beneficial ownership to 2,718.648 units.

Vertex Pharmaceuticals director Bruce I. Sachs acquired 107.088 deferred stock units, increasing his beneficial ownership to 15,564.521 units.

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold 4,500 shares of common stock for $474.99 per share under a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' EVP and CFO, Charles F. Wagner Jr., exercised stock options and subsequently sold an equal number of common shares under a pre-arranged trading plan.

Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals, sold 347 shares of common stock for $449 per share under a pre-arranged trading plan.

Vertex Pharmaceuticals' EVP, Charles F. Wagner Jr., sold 14,000 shares of common stock for approximately $6.38 million through a pre-arranged 10b5-1 trading plan.

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold 4,500 shares of common stock for approximately $449.99 per share.

Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden exercised stock options and sold a significant portion of his holdings totaling over $28 million under a pre-arranged trading plan.

Vertex Pharmaceuticals Director Lloyd Carney reported gifting 800 shares of common stock on November 19, 2025, reducing his direct beneficial ownership to 6,315 shares.

Edward Atkinson, EVP and Chief Technical Operations Officer at Vertex Pharmaceuticals, sold 2,500 shares of common stock for $434.58 per share as part of a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden exercised stock options and subsequently sold a significant number of shares under a pre-arranged trading plan.